FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce

Insmed (INSM) announced FDA Priority Review for ARIKAYCE in MAC lung disease, based on positive Phase 3b ENCORE trial results. The company projects $4.1B revenue and $1.0B earnings by 2029, with ARIKAYCE potentially expanding its rare disease portfolio. Analysts' views vary, with some forecasting slower uptake. The FDA decision is expected by January 28, 2027.

Insmed stock rose 2.0% in pre-market trading after the FDA accepted and granted Priority Review to its sNDA for ARIKAYCE, targeting a decision by January 28, 2027. The application seeks full approval for the drug, backed by Phase 3b ENCORE study results. Full approval would expand ARIKAYCE's use to newly diagnosed patients and those with recurrent infections. Insmed also plans to engage Japan's pharmaceutical regulator in Q4 2026 for potential label expansion.

Insmed Inc. (NASDAQ:INSM) shares rose 2% premarket after the FDA granted priority review to its sNDA for Arikayce, targeting MAC lung disease. The FDA set a review deadline of January 28, 2027. Arikayce, approved in 2018, could see expanded use if the application succeeds. The sNDA is backed by Phase 3b ENCORE study results showing significant improvements in respiratory symptoms and culture conversion.

Insmed Inc. (INSM) announced the FDA granted Priority Review to its sNDA for ARIKAYCE to treat MAC lung disease, with a PDUFA action date of January 28, 2027. The application is based on positive Phase 3b ENCORE study results, which showed significant improvements in respiratory symptoms and culture conversion. Full approval could expand ARIKAYCE's use to earlier-stage patients. The FDA initially approved ARIKAYCE in 2018 under accelerated pathways for refractory MAC lung disease.

Insmed (INSM) shares rose 3.1% today, likely due to positive investor conference messaging and strong respiratory franchise momentum. Management raised peak sales outlook to over $14B and adjusted 2026 BRINSUPRI revenue guidance to $1.25B-$1.40B. The company reported $1.2B in cash as of June 30, 2026.

Insmed Incorporated raised its peak sales guidance to $14 billion, citing strong performance of BRINSUPRI and TPIP. The company expects profitability next year, driven by these drugs' market potential and rapid patient uptake. This update was shared at the 12th Annual Cantor Fitzgerald Global Healthcare Conference.